Oppenheimer Positive on Endologix (ELGX) After Meeting with Management; Very Impressive Pipeline
Tweet Send to a FriendGet Alerts ELGX Hot Sheet
Price: $14.40 +0.63%
Rating Summary:
9 Buy, 0 Hold, 0 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 11 | Down: 26 | New: 12
Rating Summary:
9 Buy, 0 Hold, 0 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 11 | Down: 26 | New: 12
Trade ELGX Now!
Oppenheimer maintains an 'Outperform' on Endologix (NASDAQ: ELGX) price target of $17.00.
Analyst, Steven Lichtman, said, "We recently hosted meetings with ELGX management and came away confident that this growth story remains very much in tact: Abdominal aortic aneurysm (AAA) market volumes/pricing remain solid, ELGX's sales force is gaining in strength and the company's competition trails in the development of pipeline products to rival Nellix or Ventana. Moreover, we believe the Street is still underestimating Nellix’s potential in mainstream AAA. All told, we forecast >25% sales growth over the next five years. We remain buyers ahead of several 2H pipeline catalysts including approvals of Nellix (EU), PEVAR (US), Intuitrak (Japan) and Ventana (EU)."
For an analyst ratings summary and ratings history on Endologix click here. For more ratings news on Endologix click here.
Shares of Endologix closed at $14.33 yesterday, with a 52 week range of $7.25-$15.29.
Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW
*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here
Analyst, Steven Lichtman, said, "We recently hosted meetings with ELGX management and came away confident that this growth story remains very much in tact: Abdominal aortic aneurysm (AAA) market volumes/pricing remain solid, ELGX's sales force is gaining in strength and the company's competition trails in the development of pipeline products to rival Nellix or Ventana. Moreover, we believe the Street is still underestimating Nellix’s potential in mainstream AAA. All told, we forecast >25% sales growth over the next five years. We remain buyers ahead of several 2H pipeline catalysts including approvals of Nellix (EU), PEVAR (US), Intuitrak (Japan) and Ventana (EU)."
For an analyst ratings summary and ratings history on Endologix click here. For more ratings news on Endologix click here.
Shares of Endologix closed at $14.33 yesterday, with a 52 week range of $7.25-$15.29.
Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW
*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here
You May Also Be Interested In
- KeyBank Upgrades MDC Holdings (MDC); Cuts PulteGroup (PHM) & Ryland Group (RYL)
- UPDATE: UBS Downgrades Carnival (CCL) to Neutral; Worst May Not Be Behind
- Best Buy (BBY) Numbers Raised at Jefferies Post Q1
Create E-mail Alert Related Categories
Analyst Comments
Login with Facebook
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
